Symptoms from cancer are often best palliated by multimodal therapies performed by different physicians.

With technological advances re-irradiation has rapidly become common and an important part of cancer management to new or recurrent tumors, yet is clinically challenging given risks of serious toxicity from cumulative doses.

Radiopharmaceutical Therapy (RPT) is an emerging modality with significant potential to impact future oncological management across many disease settings.

Theranostics, a treatment paradigm pairing diagnostic molecular imaging with radiopharmaceutical therapy (RPT), is resurgent, mainly driven by the FDA approvals of 177Lu-dotatate for neuroendocrine tumors and 177Lu-PSMA-617 for prostate cancer.

Radiation dosimetry plays a critical role in the development and application of radiotherapeutic pharmaceuticals, ensuring both efficacy and safety in treatment.

Radiopharmaceuticals are an increasingly utilized therapeutic option for the treatment of malignancies.

Exercise has been shown to improve numerous physical, psychosocial and clinical outcomes in those diagnosed with cancer.

Patient reported outcomes (PROs) are a key component of evaluating cancer therapy. For clinical trialists, the proper design, implementation and evaluation of patient reported outcomes is critical for designing studies that will impact and inform daily practice.

We have observed the evolution of spatially fractionated radiotherapy (SFRT) primarily to manage metastatic cancer patients in the palliative care setting. Given recent advances in how SFRT can be delivered, can this therapeutic modality be optimized beyond the palliative care setting?

Updates in the treatment of pediatric neuroblastoma and Wilms Tumor are presented, highlighting recent practice-changing publications and evolving study questions.